1. Home
  2. FSP vs ANVS Comparison

FSP vs ANVS Comparison

Compare FSP & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Street Properties Corp.

FSP

Franklin Street Properties Corp.

HOLD

Current Price

$0.64

Market Cap

72.4M

Sector

Real Estate

ML Signal

HOLD

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$1.99

Market Cap

60.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSP
ANVS
Founded
1981
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.4M
60.1M
IPO Year
2001
2019

Fundamental Metrics

Financial Performance
Metric
FSP
ANVS
Price
$0.64
$1.99
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
270.3K
1.4M
Earning Date
04-28-2026
05-12-2026
Dividend Yield
6.34%
N/A
EPS Growth
15.69
39.39
EPS
N/A
N/A
Revenue
$107,162,000.00
N/A
Revenue This Year
$17.91
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$1.42
52 Week High
$1.88
$5.50

Technical Indicators

Market Signals
Indicator
FSP
ANVS
Relative Strength Index (RSI) 44.86 50.44
Support Level $0.58 $1.92
Resistance Level $0.71 $2.99
Average True Range (ATR) 0.04 0.12
MACD 0.00 0.04
Stochastic Oscillator 36.15 97.30

Price Performance

Historical Comparison
FSP
ANVS

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Share on Social Networks: